Royalty Report: Drugs, Biotechnology, Disease – Collection: 27665

$100.00

Curated Royalty Rate Report
Created On: 2020-07-15, Record Count: 4

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Created On: 2020-07-15
Record Count: 4

Primary Industries

  • Drugs
  • Biotechnology
  • Disease
  • Therapeutic
  • Diagnostic Substances
  • Diagnostic
  • Technical Know How

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 27665

License Grant
The sublicense agreement is for the research, development and commercialization of Altropane.
License Property
Altropane is an iodine-123 radiolabeled imaging agent which is being developed as an aid in the diagnosis of Parkinson’s disease and movement disorders. Altropane and is a molecular imaging program focused on the diagnosis of i) Parkinsonian Syndromes, or PS, including Parkinson’s Disease, or PD, and ii) Dementia with Lewy Bodies, or DLB.

IPSCIO Record ID: 6572

License Grant
Pursuant to an agreement dated February 9, 2009 between the Company, and the Licensor, a California Corporation, the Licensee, is obligated to make payments, from earnings generated from Research derived from the biological specimens from Parkinson's disease patients and control patients provided by the Licensor.
License Property
IP relates to biomarkers for Parkinson's disease.
Field of Use
The Field of Use apply to the healthcare industry.  Licensee has an ongoing collaboration with the Parkinson’s Institute to test known Parkinson’s Disease (PD) patients’ blood to identify biomarkers for Parkinson’s Disease from the human plasma proteome microarray marketed as PlasmaScanâ„¢.  Licensee is also using the H25K Whole Human Genome Microarray to examine PD samples and has identified the world’s first functional mRNA biomarkers for Parkinson’s Disease. An expanded patient study will be used to further validate the PD biomarkers.  Licensee is also working with Stanford University to test known Alzheimer’s patients’ blood to identify biomarkers for Alzheimer’s Disease using PlasmaScan and other tools.

IPSCIO Record ID: 224822

License Grant
The Licensor has granted the Irish Licensee an exclusive, sublicensable, worldwide license for its joint ownership interest in certain patents jointly owned with the Licensee. Those patents relate to the Licensees program targeting a-synuclein for the treatment of neurodegenerative disorders such as Parkinson’s disease.
License Property
The protein a-synuclein is found extensively in neurons and is a major component of pathological inclusions that characterize several neurodegenerative disorders, including Parkinson’s disease, dementia with Lewy bodies, and multiple system atrophy.
Field of Use
The Irish Licensee will generate revenues through development and commercialization.

IPSCIO Record ID: 3499

License Grant
A Swiss licensee and an Irish licensor announced a worldwide, exclusive collaboration to develop and commercialize antibodies that target alpha-synuclein, including PRX002. The license is granting rights to develop, make, have made, use, sell, offer to sell, import, and export the Licensed Products. Licensor will retain certain rights to conduct development of the Licensed Products and an option to co-promote PRX002.

Also as part of the agreement, the companies will initiate a research collaboration focused on optimizing early stage antibodies targeting alpha-synuclein including incorporation of licensee's proprietary Brain Shuttleâ„¢ technology to increase delivery of therapeutic antibodies to the brain.

License Property
PRX002 is a monoclonal antibody for the treatment of Parkinsons disease, which is currently in preclinical development and is expected to enter Phase 1 clinical trials in patients with Parkinsons disease in 2014.  

Synuclein proteins are a family of charged proteins found throughout the body. One protein from this family, alpha-synuclein, is found extensively in neurons and is a major component of pathological inclusions that characterize several neurodegenerative disorders, including Parkinson's disease, dementia with Lewy bodies, neurodegeneration with brain iron accumulation type 1, and multiple system atrophy, which collectively are termed synucleinopathies.

Field of Use
The rights granted apply to the medical industry.  Also as part of the agreement, the companies will initiate a research collaboration focused on optimizing early stage antibodies targeting alpha-synuclein including incorporation of licensee's proprietary Brain Shuttleâ„¢ technology to increase delivery of therapeutic antibodies to the brain.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.